Long-term metformin use is associated with decreased risk of breast cancer
- PMID: 20299480
- PMCID: PMC2875444
- DOI: 10.2337/dc09-1791
Long-term metformin use is associated with decreased risk of breast cancer
Abstract
Objective: To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women.
Research design and methods: Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral antidiabetes drugs with type 2 diabetes. We evaluated whether they had an altered risk of breast cancer in relation to use of various types of oral hypoglycemic agents. Case and control patients with a recorded diagnosis of type 2 diabetes were matched on age, calendar time, and general practice, and the multivariate conditional logistic regression analyses were further adjusted for use of oral antidiabetes drugs, insulin, estrogens, smoking BMI, diabetes duration, and HbA1c (A1C).
Results: We identified 305 case patients with a recorded incident diagnosis of breast cancer. The mean +/- SD age was 67.5 +/- 10.5 years at the time of the cancer diagnosis. Long-term use of >or=40 prescriptions (>5 years) of metformin, based on 17 exposed case patients and 120 exposed control patients, was associated with an adjusted odds ratio of 0.44 (95% CI 0.24-0.82) for developing breast cancer compared with no use of metformin. Neither short-term metformin use nor use of sulfonylureas or other antidiabetes drugs was associated with a materially altered risk for breast cancer.
Conclusions: A decreased risk of breast cancer was observed in female patients with type 2 diabetes using metformin on a long-term basis.
Comment in
-
Cancer: Long-term use of metformin could protect against breast cancer.Nat Rev Endocrinol. 2010 Jul;6(7):356. doi: 10.1038/nrendo.2010.79. Nat Rev Endocrinol. 2010. PMID: 20583343 No abstract available.
Similar articles
-
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):101-11. doi: 10.1158/1055-9965.EPI-10-0817. Epub 2010 Nov 30. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21119073
-
[Anti-cancer activity of metformin: new perspectives for an old drug].Rev Med Suisse. 2010 Sep 1;6(260):1601-7. Rev Med Suisse. 2010. PMID: 20853715 Review. French.
-
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976543 Review.
-
Is it time to test metformin in breast cancer prevention trials? A reply to the authors.Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2565; author reply 2565. doi: 10.1158/1055-9965.EPI-09-0515. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19745224 No abstract available.
-
[Metformin role in the treatment of type 2 diabetes in 2008].Rev Med Suisse. 2008 Jun 4;4(160):1392-4, 1396-7. Rev Med Suisse. 2008. PMID: 18630062 Review. French.
Cited by
-
Metabolic requirements for cancer cell proliferation.Cancer Metab. 2016 Aug 18;4:16. doi: 10.1186/s40170-016-0156-6. eCollection 2016. Cancer Metab. 2016. PMID: 27540483 Free PMC article.
-
Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.Cancer Causes Control. 2016 May;27(5):709-20. doi: 10.1007/s10552-016-0744-3. Epub 2016 Apr 6. Cancer Causes Control. 2016. PMID: 27053250 Free PMC article.
-
The effect of metformin and thiazolidinedione use on lung cancer in diabetics.BMC Cancer. 2012 Sep 14;12:410. doi: 10.1186/1471-2407-12-410. BMC Cancer. 2012. PMID: 22978440 Free PMC article.
-
Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer.Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1802-1808. doi: 10.1158/1055-9965.EPI-19-0291. Epub 2019 Aug 8. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31395589 Free PMC article.
-
CISD1 Is a Breast Cancer Prognostic Biomarker Associated with Diabetes Mellitus.Biomolecules. 2022 Dec 25;13(1):37. doi: 10.3390/biom13010037. Biomolecules. 2022. PMID: 36671422 Free PMC article.
References
-
- Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007;86:s823–s835 - PubMed
-
- Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23–37 - PubMed
-
- Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 2006;98:303–309 - PubMed
-
- Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42–51 - PubMed
-
- Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE: The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008;109:389–395 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical